Clinical Trials Browser

Phase 1/2 × Carcinoma, Hepatocellular × Erlotinib Hydrochloride × Clear all

NCT02273362 2024-03-26

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Phase 1/2 Completed

25 enrolled 10 charts

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

NCT00293436 2012-09-17

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00791544 2010-08-04

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular